Denali Therapeutics DNLI
NASDAQ DNLI
$18.63 -0.31 (-1.61%)
As of: Oct 21, 2026 · 3:01 PM EDT

Denali Therapeutics (DNLI) Gross Margin (2026)

Updated

Denali Therapeutics (DNLI) recorded Gross Margin of 97.42% in Q2 2026.

Analysis

Denali Therapeutics (DNLI) Gross Margin (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Eli Lilly 1,136.82 Bn 1,105.41 Bn 19.71 Bn 85.78%
2 Johnson & Johnson 617.41 Bn 535.94 Bn 17.26 Bn 68.19%
3 AbbVie 501.29 Bn 474.40 Bn 12.70 Bn 74.74%
4 Merck 368.15 Bn 322.53 Bn 12.21 Bn 73.54%
5 Novartis Ag 297.07 Bn 261.06 Bn 11.24 Bn 78.02%
6 Astrazeneca 260.90 Bn 234.58 Bn 12.86 Bn 83.60%
7 Amgen 236.34 Bn 191.74 Bn 7.24 Bn 72.04%
8 Gilead Sciences 191.00 Bn 165.20 Bn 6.22 Bn 79.76%
9 Pfizer 169.72 Bn 116.36 Bn 10.94 Bn 72.78%
10 Denali Therapeutics 3.48 Bn 67.94 Mn 3.51 Mn 97.42%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.42%
API Access

Denali Therapeutics Gross Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gross-margin&ticker=DNLI&period=max&api_key=YOUR_API_KEY